The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Exploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Abstract
RATIONALE: For many patients with asthma, allergic airway inflammation is primarily a Th2-weighted process; however, heterogeneity in patterns of inflammation suggests phenotypic distinctions exist that influence disease presentation and treatment effects. OBJECTIVES: To assess the potential of fractional exhaled nitric oxide (FE(NO)), peripheral blood eosinophil count, and serum periostin as biomarkers of Th2 inflammation and predictors of treatment effects of omalizumab. METHODS: The EXTRA omalizumab study enrolled patients (aged 12-75 yr) with uncontrolled severe persistent allergic asthma. Analyses were performed evaluating treatment effects in relation to FE(NO), blood eosinophils, and serum periostin at baseline. Patients were divided into low- and high-biomarker subgroups. Treatment effects were evaluated as number of protocol-defined asthma exacerbations during the 48-week treatment period (primary endpoint). MEASUREMENTS AND MAIN RESULTS: A total of 850 patients were enrolled. Data were available from 394 (46.4%), 797 (93.8%), and 534 (62.8%) patients for FE(NO), blood eosinophils, and serum periostin, respectively. After 48 weeks of omalizumab, reductions in protocol-defined exacerbations were greater in high versus low subgroups for all three biomarkers: FE(NO), 53% (95% confidence interval [CI], 37-70; P = 0.001) versus 16% (95% CI, -32 to 46; P = 0.45); eosinophils, 32% (95% CI, 11-48; P = 0.005) versus 9% (95% CI, -24 to 34; P = 0.54); and periostin, 30% (95% CI, -2 to 51; P = 0.07) versus 3% (95% CI, -43 to 32; P = 0.94). CONCLUSIONS: The difference in exacerbation frequency between omalizumab and placebo was greatest in the three high-biomarker subgroups, probably associated with the greater risk for exacerbations in high subgroups. Additional studies are required to explore the value of these biomarkers in clinical practice. Clinical trial registered with www.clinicaltrials.gov (NCT00314574).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Standardization of Spirometry, 1994 Update. American Thoracic Society.
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.3.7663792 · Cited by 6,594
Dweik, R. A., Boggs, P. B., Erzurum, S. C., Irvin, C. G., Leigh, M. W., Lundberg, J. O., Olin, A.-C., Plummer, A. L., & Taylor, D. R. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.9120-11st · Cited by 2,539
Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-060st · Cited by 1,918
Self-citationDetermining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Self-citationAsthma: From Bronchoconstriction to Airways Inflammation and Remodeling
BOUSQUET, J., JEFFERY, P. K., BUSSE, W. W., JOHNSON, M., & VIGNOLA, A. M. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.5.9903102 · Cited by 1,702
Self-citationCan Guideline-defined Asthma Control Be Achieved?: The Gaining Optimal Asthma ControL Study
Bateman, E. D., Boushey, H. A., Bousquet, J., Busse, W. W., Clark, T. J. H., Pauwels, R. A., & Pedersen, S. E. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-033oc · Cited by 1,594
Self-citationLebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Self-citationBusse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Self-citationHumbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00772.x · Cited by 1,123
The cytokine network in asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36130 · Cited by 982
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 884
Self-citationSolèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
Significant variability in response to inhaled corticosteroids for persistent asthma
Szefler, S. J., Martin, R. J., King, T. S., Boushey, H. A., Cherniack, R. M., Chinchilli, V. M., Craig, T. J., Dolovich, M., Drazen, J. M., Fagan, J. K., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.122635 · Cited by 622
Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients
Jia, G., Erickson, R. W., Choy, D. F., Mosesova, S., Wu, L. C., Solberg, O. D., Shikotra, A., Carter, R., Audusseau, S., Hamid, Q., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.06.025 · Cited by 615
Self-citationHanania, N. A., Alpan, O., Hamilos, D. L., Condemi, J. J., Reyes-Rivera, I., Zhu, J., Rosen, K. E., Eisner, M. D., Wong, D. A., & Busse, W. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00002 · Cited by 554
Self-citationHolgate, S. T., Chuchalin, A. G., Hébert, J., Lötvall, J., Persson, G. B., Chung, K. F., Bousquet, J., Kerstjens, H. A., Fox, H., Thirlwell, J., et al. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.1916.x · Cited by 522
Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., Fox, H., Hedgecock, S., Blogg, M., & Cioppa, G. D. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00770.x · Cited by 401
Self-citationSzefler, S. J., Wenzel, S., Brown, R., Erzurum, S. C., Fahy, J. V., Hamilton, R. G., Hunt, J. F., Kita, H., Liu, A. H., Panettieri, R. A., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.12.979 · Cited by 395
Self-citationLanier, B., Bridges, T., Kulus, M., Taylor, A. F., Berhane, I., & Vidaurre, C. F. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.021 · Cited by 360
Predicting and evaluating response to omalizumab in patients with severe allergic asthma
Bousquet, J., Rabe, K., Humbert, M., Chung, K. F., Berger, W., Fox, H., Ayre, G., Chen, H., Thomas, K., Blogg, M., et al. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2007.01.011 · Cited by 304
Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma
Bousquet, J., Wenzel, S., Holgate, S., Lumry, W., Freeman, P., & Fox, H. (2004) · Chest · doi:10.1378/chest.125.4.1378 · Cited by 277
Self-citationSafety and tolerability of omalizumab
Corren, J., Casale, T. B., Lanier, B., Buhl, R., Holgate, S., & Jimenez, P. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03214.x · Cited by 252
Chibana, K., Trudeau, J. B., Mustovitch, A. T., Hu, H., Zhao, J., Balzar, S., Chu, H. W., & Wenzel, S. E. (2008) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.02969.x · Cited by 213
Self-citationInhibition of Allergic Reactions with Antibodies to IgE
Shields, R. L., Whether, W. R., Zioncheck, K., O’Connell, L., Fendly, B., Presta, L. G., Thomas, D., Saban, R., & Jardieu, P. (1995) · International Archives of Allergy and Immunology · doi:10.1159/000237010 · Cited by 183
Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
Bousquet, J., Siergiejko, Z., Świebocka, E., Humbert, M., Rabe, K. F., Smith, N., Leo, J., Peckitt, C., Maykut, R., & Peachey, G. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02522.x · Cited by 168
Effect of omalizumab on peripheral blood eosinophilia in allergic asthma
Massanari, M. J., Holgate, S. T., Busse, W. W., Jimenez, P. A., Kianifard, F., & Zeldin, R. K. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.09.011 · Cited by 138
Self-citationLevine, S. J., & Wenzel, S. E. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-4-201002160-00008 · Cited by 111
Self-citationCameron, L., Hamid, Q., Wright, E., Nakamura, Y., Christodoulopoulos, P., Muro, S., Frenkiel, S., Lavigne, F., Durham, S., & Gould, H. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.107398 · Cited by 107
Lazar, A., Cole, B. F., Bonetti, M., & Gelber, R. D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9182 · Cited by 103
Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma
Kulus, M., Hébert, J., García, E., Taylor, A. F., Vidaurre, C. F., & Blogg, M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003771338 · Cited by 102
Relationship between pretreatment specific IgE and the response to omalizumab therapy
Wahn, U., Martín, C., Freeman, P., Blogg, M., & Jimenez, P. A. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02119.x · Cited by 75
Lessons learned from variation in response to therapy in clinical trials
Szefler, S. J., & Martin, R. J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.026 · Cited by 45
Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma
Chung, K. F. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.2.439 · Cited by 17
Cited by
Papi, A., Brightling, C., Pedersen, S. E., & Reddel, H. K. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33311-1 · Cited by 1,759
The basic immunology of asthma
Hammad, H., & Lambrecht, B. N. (2021) · Cell · doi:10.1016/j.cell.2021.02.016 · Cited by 1,105
Treatable traits: toward precision medicine of chronic airway diseases
Agusti, A., Bel, E., Thomas, M., Vogelmeier, C., Brusselle, G., Holgate, S., Humbert, M., Jones, P., Gibson, P. G., Vestbo, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01359-2015 · Cited by 1,083
After asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Self-citationBiologic Therapies for Severe Asthma
Brusselle, G. G., & Koppelman, G. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032506 · Cited by 715
Metadata
- Authors
- Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-15
- Volume
- 187
- Issue
- 8
- Pages
- 804-811
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2121954044
- Cited by
- 901
- References
- 35
- FWCI
- 42.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.